Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (13)

2023

  1. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2021

  1. Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)

    Clinical and Translational Oncology

2020

  1. Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. SEOM clinical guidelines for the treatment of head and neck cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 75-83

2017

  1. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

    Enfermedades Infecciosas y Microbiologia Clinica

2016

  1. Management of infection and febrile neutropenia in patients with solid cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 6, pp. 557-570

  2. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

2014

  1. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

    Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421

2013

  1. Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas

    PLoS ONE, Vol. 8, Núm. 9

  2. SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)

    Clinical and Translational Oncology, Vol. 15, Núm. 1, pp. 20-25

2012

  1. Functions and workload of medical oncologists in Spain

    Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 423-429

  2. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

    Annals of Oncology, Vol. 23, Núm. 4, pp. 1016-1022

2010

  1. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

    British Journal of Cancer, Vol. 102, Núm. 12, pp. 1687-1691